KRON Kronos Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRON

Price (delayed)

$1

Market cap

$60.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.95

Enterprise value

$22.02M

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated ...

Highlights
The company's revenue has surged by 57% QoQ
Kronos Bio's gross profit has soared by 57% from the previous quarter
Kronos Bio's quick ratio has decreased by 37% YoY and by 3.5% from the previous quarter
The equity has declined by 35% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://kronosbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KRON
Market
Shares outstanding
60.1M
Market cap
$60.1M
Enterprise value
$22.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
9.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.5
Earnings
Revenue
$6.29M
EBIT
-$112.67M
EBITDA
-$107.76M
Free cash flow
-$79.26M
Per share
EPS
-$1.95
Free cash flow per share
-$1.37
Book value per share
$2.73
Revenue per share
$0.11
TBVPS
$3.69
Balance sheet
Total assets
$213.28M
Total liabilities
$54.2M
Debt
$28.27M
Equity
$159.08M
Working capital
$154.08M
Liquidity
Debt to equity
0.18
Current ratio
7.24
Quick ratio
7.09
Net debt/EBITDA
0.35
Margins
EBITDA margin
-1,713.7%
Gross margin
100%
Net margin
-1,791.9%
Operating margin
-1,937.5%
Efficiency
Return on assets
-45%
Return on equity
-58.8%
Return on invested capital
-57.5%
Return on capital employed
-59.7%
Return on sales
-1,791.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRON stock price

How has the Kronos Bio stock price performed over time
Intraday
-2.91%
1 week
0%
1 month
-20.63%
1 year
-40.48%
YTD
-20%
QTD
-23.08%

Financial performance

How have Kronos Bio's revenue and profit performed over time
Revenue
$6.29M
Gross profit
$6.29M
Operating income
-$121.83M
Net income
-$112.67M
Gross margin
100%
Net margin
-1,791.9%
The company's revenue has surged by 57% QoQ
Kronos Bio's gross profit has soared by 57% from the previous quarter
The net margin is up by 40% QoQ
The operating margin is up by 40% since the previous quarter

Growth

What is Kronos Bio's growth rate over time

Valuation

What is Kronos Bio stock price valuation
P/E
N/A
P/B
0.37
P/S
9.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.5
Kronos Bio's EPS has increased by 18% YoY and by 6% QoQ
The equity has declined by 35% year-on-year and by 11% since the previous quarter
KRON's P/B is 5% below its last 4 quarters average of 0.4
KRON's P/S is 71% below its last 4 quarters average of 32.7
The company's revenue has surged by 57% QoQ

Efficiency

How efficient is Kronos Bio business performance
Kronos Bio's return on sales has increased by 40% QoQ
The ROE fell by 24% YoY and by 5% QoQ
Kronos Bio's ROA has decreased by 11% YoY and by 2.3% from the previous quarter
The company's return on invested capital fell by 6% YoY and by 3.8% QoQ

Dividends

What is KRON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRON.

Financial health

How did Kronos Bio financials performed over time
Kronos Bio's quick ratio has decreased by 37% YoY and by 3.5% from the previous quarter
Kronos Bio's current ratio has decreased by 36% YoY and by 2.9% QoQ
The debt is 82% lower than the equity
Kronos Bio's debt to equity has increased by 38% YoY and by 6% from the previous quarter
The equity has declined by 35% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.